AnkurRasikParikhDO
Oncology • Willow Grove, PAGastrointestinal Cancer
Associate Medical Director, Precision Medicine
Dr. Parikh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Asplundh Cancer Pavilion
3941 Commerce Ave
Willow Grove, PA 19090
Summary
- I am a medical oncologist and associate medical director of precision medicine. I believe that genomic based therapy and immuno-oncology are rapidly changing the landscape of cancer treatment. I am involved with clinical research and enjoy speaking at national conferences and seminars on the topics of precision medicine and oncology.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
OhioHealth/Riverside Methodist HospitalResidency, Internal Medicine, 2006 - 2009
A. T. Still University Kirksville College of Osteopathic MedicineClass of 2006
Certifications & Licensure
PA State License 2012 - 2024
MD State License 2009 - 2013
OH State License 2006 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome Start of enrollment: 2005 Jul 21
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Start of enrollment: 2016 Mar 14
- Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2017 Mar 01
Publications & Presentations
PubMed
- 14 citationsPan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.K Murugesan, A Necchi, T C Burn, O Gjoerup, R Greenstein
ESMO Open. 2022-12-01 - 2 citationsEltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.Alana Vicente, Bhavisha A Patel, Fernanda Gutierrez-Rodrigues, Emma Groarke, Valentina Giudice
Haematologica. 2020-12-01 - 277 citationsEltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drugRonan Desmond, Danielle M. Townsley, Bogdan Dumitriu, Matthew J. Olnes, Phillip Scheinberg
Blood. 2014-03-20
Journal Articles
- Applying Genomics to Leukemias & LymphomasParikh AR, Oncology Times, 9/5/2018
- Under representation of Elderly Population in Clinical TrialsParikh AR, Oncology Times, 7/5/2018
- A Look at Cancer Immunotherapy in Elderly PatientsParikh AR, Oncology Times, 4/20/2018
Authored Content
- We need more answers about immunotherapy for elderly6/22/2018
Press Mentions
- How to Access Cutting-Edge Cancer Treatments and Clinical Trials in PhillyOctober 31st, 2020
FDA Approves Foundation Medicine’s Genetic Diagnostic Test as CMS Paves the Way for CoverageDecember 1st, 2017
Professional Memberships
- Member
- Member
- Member
External Links
- LinkedInhttp://linkedin.com/in/ankur-parikh-646749141
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
